Here are the stocks added to the Zacks #5 Rank ("strong sell") List today:

ABB Ltd (ABB) ACIW (ACIW) AnnTaylor Stores Corp (ANN) Argo Group International Holdings Ltd (AGII) Bancolombia SA (CIB) Bristow Group Inc (BRS) BRT Realty Trust (BRT) Cadence Financial Corp (CADE) CenterPoint Energy Inc (CNP) Collective Brands Inc (PSS) El Paso Electric Co (EE) Erie Indemnity Co (ERIE) Expeditors International of Washington (EXPD) Fairpoint Communications Inc (FRP) Ferro Corp (FOE) First Merchants Corp (FRME) First Security Group Inc (FSGI) Fuel Tech Inc (FTEK) Gol Linhas Aereas Inteligentes SA (GOL) Harleysville Group Inc (HGIC) Haverty Furniture Companies Inc (HVT) Heartland Payment Systems Inc (HPY) Huntsman Corp (HUN) Intrepid Potash Inc (IPI) ITT Corp (ITT) Jo-Ann Stores Inc (JAS) Kelly Services Inc ...

Capitalizing on its advanced understanding of human hearing, Sonic Innovations, Inc. (SNCI) has developed patented digital signal processing (DSP) technologies, and embedded them into the smallest single-chip DSP platform ever installed in a hearing aid. SNCI announced the launch of another version of it relatively new premium product line Velocity.We previously increased our FY08 sales and EPS estimates. We previously lowered our FY09 sales estimate but increased our FY09 EPS estimate. The company finally gave up on Tympany and the referral concept, and instead has expanded its distribution relationships and is acquiring practices and opening new clinics to help drive meaningful sales growth from new product launches.SNCI has been consolidating operations in Europe to reduce operating costs and to focus resources on markets that offer the greatest profitability. Our price target of $3.00 per share is based on a price-to-sales multiple of roughly 0.6x ...

Sonic Innovations, Inc. (SNCI) finally gave up on its auditory testing equipment unit Tympany and the referral concept and instead has expanded its distribution relationships. The sale of Tympany has helped the company clear a path to meaningful earnings growth. It is also acquiring and opening new clinics to help drive meaningful sales growth from new product launches.

The improvements made to the distribution, management and sales structure have been helping to drive meaningful sales growth. The company’s emphasis on research and development has resulted in new product launches that continue drive sales growth in the high double digits.

The weak economy continues to negatively impact North American sales. Hence, the company has been consolidating operations in Europe to reduce operating costs and to focus resources on markets that offer the greatest profitability.

At its current price of $2.93 per share, SNCI is trading at 0.6x our 2009 revenue estimate

...